Bill > HR679

This bill seeks to nullify modifications made by the Food and Drug Administration (FDA) in January 2023 to the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, a medication used for medical abortion. REMS is a safety program that the FDA can require for certain medications with potential serious side effects. Specifically, the bill would completely invalidate the FDA's January 2023 changes to the drug's safety protocol and prohibit the Department of Health and Human Services from implementing any future safety provisions for mifepristone that are substantially similar to the nullified modifications. The bill effectively aims to restrict the FDA's ability to regulate the distribution and use of mifepristone, potentially impacting access to medication abortion by preventing the agency from implementing safety guidelines it deems necessary. By targeting the REMS specifically, the bill represents a direct legislative intervention into the FDA's drug safety oversight process.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/679/all-info